Capricor Therapeutics (CAPR) Gets a Hold Rating from Maxim Group


In a report released today, Jason McCarthy from Maxim Group assigned a Hold rating to Capricor Therapeutics (CAPR). The company’s shares opened today at $0.58, close to its 52-week low of $0.31.

McCarthy observed:

“Capricor announced it has resumed dosing in the HOPE-2 trial, which is testing CAP-1002 for already enrolled patients (n=20) with Duchenne muscular dystrophy (DMD).”

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.4% and a 33.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

Currently, the analyst consensus on Capricor Therapeutics is a Moderate Buy with an average price target of $3.50.

See today’s analyst top recommended stocks >>

Based on Capricor Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $4.14 million. In comparison, last year the company had a net profit of $12.31 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts